ProCE Banner Activity

Cobimetinib + Atezolizumab Well Tolerated and Shows Promising Activity in KRAS-Mutant mCRC

Slideset Download
Conference Coverage
MEK and PD-L1 inhibitors show potential synergy in MSS and chemorefractory KRAS-mutant mCRC.

Released: June 10, 2016

Expiration: June 09, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals